12月29日，华夏基金将与泰国券商InnovestX Securities携手，在泰国证券交易所（SET）同步挂牌上 市"华夏沪深300ETF"及"华夏科创50ETF"挂钩的存托凭证（DR）。此举标志着华夏基金在上交所上市 的ETF首次以DR模式进入海外市场，也是中泰资本市场在"一带一路"框架下深化合作的又一重要进 展。此次华夏基金两支旗舰ETF产品同步登陆泰国，也充分体现了当地市场对中国优质资产与科技成长 前景的积极关注和配置信心。 与传统宽基或一般成长型指数不同，科创50指数汇聚了中国半导体、高端装备、生物医药等战略新兴产 业的龙头企业。华夏科创50ETFDR的上市，填补了东南亚市场在投资中国"硬科技"板块的空白。这不 仅让泰国投资者能直接分享中国科技转型的红利，更集中体现了国际资本对中国在关键核心技术攻关、 半导体产业链自主可控以及科技自立自强方面最新成果的高度认可。 与此同时，作为中国经济"晴雨表"的华夏沪深300ETF也同步通过DR形式登陆泰国，为海外资金提供了 一键配置中国核心优质资产的首选通道。两只产品同时上市，形成了"核心资产+硬核科技"的双轮驱动 布局。 华夏基金：持续领跑中国资产"出海"新 ...

Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board 100 Index decreased by 0.46% as of July 18, 2025, with mixed performance among constituent stocks [1] - BoRui Pharmaceutical led the gains with an increase of 6.37%, while Yuanjie Technology experienced the largest decline at 4.94% [1] - The Huaxia Sci-Tech 100 ETF (588800) fell by 0.49%, with a latest price of 1.01 yuan and a turnover rate of 5.36%, amounting to a transaction volume of 158 million yuan [1] Group 2 - CITIC Securities highlights that despite increasing external challenges, the competitiveness of China's pharmaceutical industry continues to rise, with innovative drugs gaining international recognition [2] - China possesses advantages in population and domestic demand, manufacturing and supply chain, while its innovation capabilities are rapidly improving [2] - The Huaxia Sci-Tech 100 ETF (588800) shows that stocks with a market capitalization below 20 billion yuan account for 80% of its holdings, indicating a focus on small-cap stocks [2]